




What's New in Research?

Claire Sexton, D.Phil.

Senior Director, Scientific Programs & Outreach

What's the difference between Alzheimer's and dementia?



Dementia is an *umbrella term* used to describe a range of symptoms, including changes in memory, thinking and behavior.

In order for a diagnosis of dementia to be made, symptoms must be severe enough to interfere with daily life.

There are many causes or types of dementia, including Alzheimer's, vascular, Lewy body, and frontotemporal dementia.

Alzheimer's disease is the most common cause of dementia and is characterised by **amyloid plaques, tau tangles** and **cell loss**.




Earliest Alzheimer's

Changes may begin
10-20 years before diagnosis



Mild-Moderate Alzheimer's

May last from 2-10 years



Severe Alzheimer's

May last from 1-5 years

The 2023 Alzheimer's Disease Facts and Figures Report illustrates the **extent and impact** of **Alzheimer's and dementia** in the U.S.

More than

6 million

Americans are living
with Alzheimer's

Over

11 million

Americans provide
unpaid care

Alzheimer's and other
dementias will cost the
nation

\$340 billion

Alzheimer's is one of the greatest threats to women's health.



Almost **TWO-THIRDS** of Americans living with Alzheimer's are women.

ALZHEIMER'S  ASSOCIATION®



MORE THAN 60% of Alzheimer's and dementia caregivers are women.

ALZHEIMER'S  ASSOCIATION®




Over **ONE-THIRD** of dementia caregivers are daughters.

ALZHEIMER'S  ASSOCIATION®



In the United States, **MORE THAN 10 MILLION WOMEN** are either living with Alzheimer's or caring for someone who has it.

ALZHEIMER'S  ASSOCIATION®




Behind the Headlines

1. Anti-amyloid therapies

2. Therapeutic landscape

3. Biomarkers

4. Modifiable Factors



Behind the Headlines

1. Anti-amyloid therapies

2. Therapeutic landscape

3. Biomarkers

4. Modifiable Factors

Positive Treatment Data, Lecanemab Brings Hope and Enthusiasm

October, 2022



Maria Carrillo
Alzheimer's Association

“We are living in **historic times for Alzheimer’s**”

In the 18-month Phase 3 CLARITY AD clinical trial of lecanemab... **Amyloid build-up was reduced in the brain... [and] lecanemab reduced clinical decline compared with placebo by 27%**

5 Important Things to Know About CMS' Decision to Block Access to Alzheimer's Treatments

April, 2023



This is the **1st time in history** that Medicare has refused to cover a drug that has been given FDA approval...

Each day CME denies access to FDA-approved Alzheimer's treatments, more than 2,000 **people transition out of eligibility.**

Donanemab Phase 3 Topline Results Are Positive

May, 2023



Joanne Pike
Alzheimer's Association

Donanemab **slowed clinical decline by 35%** compared to placebo... and resulted in **40% less decline in the ability to perform activities of daily living.**

“We must wait until July for the full report on results... **We will not rest** until everyone on Medicare can count on the same coverage for Alzheimer’s treatments as they do for other diseases.”

Alzheimer's Association Launches ALZ-NET: A Long-Term Data Collection and Sharing Network for New Treatments


August, 2022



Gil D. Rabinovici
UCSF, USA

“ALZ-NET will gather **real-world clinical practice data and outcomes**, including treatment effectiveness and side effects...

ALZ-NET will include people from a variety of backgrounds and communities to **achieve representativeness beyond the populations historically enrolled in clinical trials**”



Behind the Headlines

1. Anti-amyloid therapies

2. Therapeutic landscape

3. Biomarkers

4. Modifiable Factors

Dr. Ross Paterson Shares His Research Funded by Alzheimer's Association Part the Cloud Grant

February, 2023



Dr Ross Paterson
University College London, UK

“It's a hugely exciting time to be in Alzheimer's disease therapeutics

My latest study involves... a treatment that would **stop tau production.**”


Alzheimer's Association Makes Bold Investment in Venture Capital Fund to Accelerate Development of New Treatments

April, 2023



Dr Maria Carrillo
Alzheimer's Association

“With this (€10 million) commitment, the Alzheimer's Association is expanding our funding in varied and broader areas of dementia drug development to **advance and diversify** the pipeline”



Behind the Headlines

1. Anti-amyloid therapies

2. Therapeutic landscape

3. **Biomarkers**

4. Modifiable Factors

Alzheimer's Association Global Workgroup Releases Recommendations About Use of Alzheimer's "Blood Tests"

July 2022



Dr Oskar Hansson
Lund University, Sweden

“Blood-based biomarkers for Alzheimer’s are already improving the design of clinical trials, and they are **very likely to revolutionize the diagnosis of Alzheimer’s in the future...** That said... Much **more research is needed** before widespread clinical use.”



Behind the Headlines

1. Anti-amyloid therapies

2. Therapeutic landscape

3. Biomarkers

4. **Modifiable Factors**

Landmark U.S. Pointer Study Completes Recruitment of 2,000+ Participants, Including 30% from Underrepresented Communities


March 2023



Dr Laura Baker
Wake Forest University, USA

U.S. POINTER is a **two-year clinical trial** to evaluate whether **lifestyle interventions** that target many risk factors can **protect cognitive function** in older adults who are at increased risk for cognitive decline.

“First, we must acknowledge and celebrate those who have volunteered for the study. They are the heart and soul of this effort.”



Behind the Headlines

1. Anti-amyloid therapies

2. Therapeutic landscape

3. Biomarkers

4. Modifiable Factors

The Alzheimer's Association **seed, speed and scale** scientific advances through our **grant programs**.

We are the largest nonprofit funder of Alzheimer's and all dementia research in the world

1,000

projects


54

countries

\$320

million currently active

The Alzheimer's Association's International Society To Advance Alzheimer's Research and Treatment has over **8,500 members**.



ALZHEIMER'S ASSOCIATION

AAIC > 23


ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE®

AMSTERDAM, NETHERLANDS, AND ONLINE > JULY 16-20

Preconferences: July 14-15 > Exhibits: July 16-19

alz.org/AAIC

Access the latest dementia science using the Alzheimer's Association Science Hub App



The **Alzheimer's Association Science Hub** is a **free app** that provides the latest news, information and expert views about Alzheimer's and dementia research

Find opportunities to **participate** in research
through **TrialMatch**.



TrialMatch is a free, easy-to-use platform that
provides **customized lists of clinical studies**.



Goals of the Alzheimer's Association's Health Systems Initiative:

- To support providers with strategies and solutions that can ensure quality care for people living with dementia
- To understand the needs of providers so we can help them meet the complex care needs of individuals and families

The Alzheimer's Association supports health systems to better:



assess
cognition,



provide a timely
diagnosis of
Alzheimer's or
other dementias,



and efficiently direct
patient management, and
improve care outcomes.



Thank you!

For more information visit [alz.org](https://www.alz.org)